872 related articles for article (PubMed ID: 16103469)
1. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
Eddy DM; Schlessinger L; Kahn R
Ann Intern Med; 2005 Aug; 143(4):251-64. PubMed ID: 16103469
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
[TBL] [Abstract][Full Text] [Related]
3. Summaries for patients. The outcomes and costs of diabetes prevention with a diet and exercise program or metformin: a computer model.
Ann Intern Med; 2005 Aug; 143(4):I22. PubMed ID: 16103465
[No Abstract] [Full Text] [Related]
4. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.
Diabetes Prevention Program Research Group
Diabetes Care; 2003 Sep; 26(9):2518-23. PubMed ID: 12941712
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the cost-effectiveness of lifestyle modification versus metformin therapy for the prevention of diabetes in Singapore.
Png ME; Yoong JS
PLoS One; 2014; 9(9):e107225. PubMed ID: 25203633
[TBL] [Abstract][Full Text] [Related]
6. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom.
Palmer AJ; Roze S; Valentine WJ; Spinas GA; Shaw JE; Zimmet PZ
Clin Ther; 2004 Feb; 26(2):304-21. PubMed ID: 15038953
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of a Stepwise Approach vs Standard Care for Diabetes Prevention in India.
Islek D; Weber MB; Ranjit Mohan A; Mohan V; Staimez LR; Harish R; Narayan KMV; Laxy M; Ali MK
JAMA Netw Open; 2020 Jul; 3(7):e207539. PubMed ID: 32725244
[TBL] [Abstract][Full Text] [Related]
8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
9. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
Palmer AJ; Tucker DM
Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM
Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review.
Zhou X; Siegel KR; Ng BP; Jawanda S; Proia KK; Zhang X; Albright AL; Zhang P
Diabetes Care; 2020 Jul; 43(7):1593-1616. PubMed ID: 33534726
[TBL] [Abstract][Full Text] [Related]
12. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Diabetes Prevention Program Research Group
Diabetes Care; 2012 Apr; 35(4):723-30. PubMed ID: 22442395
[TBL] [Abstract][Full Text] [Related]
13. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
Flórez H
Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
[TBL] [Abstract][Full Text] [Related]
14. Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation.
Thomas C; Sadler S; Breeze P; Squires H; Gillett M; Brennan A
BMJ Open; 2017 Aug; 7(8):e014953. PubMed ID: 28827235
[TBL] [Abstract][Full Text] [Related]
15. Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000.
Icks A; Rathmann W; Haastert B; Gandjour A; Holle R; John J; Giani G;
Diabet Med; 2007 May; 24(5):473-80. PubMed ID: 17381502
[TBL] [Abstract][Full Text] [Related]
16. Achievable cost saving and cost-effective thresholds for diabetes prevention lifestyle interventions in people aged 65 years and older: a single-payer perspective.
Anderson JM
J Acad Nutr Diet; 2012 Nov; 112(11):1747-54. PubMed ID: 23102174
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study.
Herman WH
Clin Diabetes Endocrinol; 2015; 1():9. PubMed ID: 28702228
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
Caro JJ; Getsios D; Caro I; Klittich WS; O'Brien JA
Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
